

REFERENCES

- Aaberg TM:** Management of anterior and posterior proliferative vitreoretinopathy. Am J Ophthalmol 1988; 106: 519-532.
- Abrams GW and Glazer LC:** Proliferative vitreoretinopathy. In Freeman WR (ed.): Practical atlas of retinal disease and therapy (second addition), Lippincott-Raven, Philadelphia, USA, 1998, pp 303-323.
- Adel SS:** Minimal extraocular surgery in retinal detachment with proliferative vitreoretinopathy. Bull Ophthalmol Soc Egypt 2001; 94 : 493 -7.
- Akpek EK, Hasiripi H, Christen WG, and Kalayci D:** A randomized trial of low dose topical mitomycin C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology 2000; 107 : 263-7
- Alexander RA, Hiscott P, McGalliard J and Grierson I:** Oxylatan fibers in proliferative vitreoretinopathy. Ger J Ophthalmol 1992; 1: 382-387.
- Ali KG and Zaki I :** Toxic effects of intravitreal 5-fluorouracil and mitomycin C on rabbit eyes. Bull Ophthalmol Soc Egypt 1995; 88 : 839 – 44.
- Alio JL and BenEzra D:** Intraocular inflammation : is there any light at the end of the tunnel ? Highlights of Ophthalmology 2002; 30 : 2 - 7.
- Alvira G, Hartzel M and Blumenkranz M:** Heparin : a possible new aproach to the treatment of proliferative vitreoretinopathy. In :

Proliferative vitreoretinopathy. Heimann K, Weidemann P (eds). Heidelberg, Germany: Kaden Verlag, 1989 : 268 – 71.

Antoszyk AN and McCuen BW II: Vitreous surgery in proliferative vitreoretinopathy. In : Duane's Ophthalmology (CD-Rom edition). Tasman W, Jaeger EA (ed.). 530 Walnut Street Philadelphia, PA 19106 : Lippincott Williams and Wilkins publishers Inc., 2002; Chapter 58.

Araiz JJ, Refojo MF and Arroyo M: Antiproliferative effect of retinoic acid in intravitreal silicone oil in an animal model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1993; 34 : 522 – 30.

Asaria RHY, Kon CH and Bunce C : Silicone oil concentrates fibrogenic growth factors in the retro – oil fluid. Br J Ophthalmol 2004; 88 : 1439 – 42.

Asaria RHY, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT and Ayelward GW: Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy. Ophthalmology 2001b; 108 : 1179- 83.

Asaria RHY, Kon CH, Bunce C, et al: How to predict proliferative vitreoretinopathy- a prospective study. Ophthalmology 2001 a; 108: 1184-1186.

Ayelward GW: Proliferative vitreoretinopathy. In : Ophthalmology (second edition). Yanoff M, Duker JS (eds) 11830 Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc., 2004 : 1002 – 6.

- Ayelward GW:** Retinal detachment: Proliferative vitreoretinopathy In Yanoff M, Duker JS (eds.): Ophthalmology (1st ed.). Mosby, section 8.42, London, UK, 1999, pp 1-6.
- Azen SP, Scott IU and Flynn H.:** Silicone oil in the repair of complex retinal detachments : a prospective, observational, multicenter study. Ophthalmology 1998; 105 : 1587 – 97.
- Baird A and Klagsburn M:** The fibroblast growth factor family – an overview. Ann NY Acad Sci 1991; 638: xi-xii.
- Barr CC, Stern W and Lai My for Silicon Study Group:** Postoperative intraocular pressure abnormalities in the silicone study. Silicone Study report 4. Ophthalmology 1993; 100 : 1629 – 35.
- Bassat IB, Desatnik H, Alhalel A, Treister G and Moissiev J:** Reduced rate of retinal detachment following silicone oil removal : Retina 2000; 20 : 597 – 603.
- Baudouin C, Fredj-Reygrobellet D, Gordon W, et al:** Immunohistologic study of epiretinal membrane in proliferative vitreoretinopathy. Am J ophthalmol 1990; 110:593-598.
- Blankenship GW:** Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases. Graefes Arch Clin Exp Ophthalmol 1989; 227 : 565 -8.
- Blumenkranz M, Hartzel MK and Hajek AS:** Selection of therapeutic agents for intraocular proliferative disease: II. Differing antiproliferative activity of the fluoropyrimidines. Arch Ophthalmol 1987; 105: 369-399.

Blumenkranz MS and Hartzel MK: Pharmacologic treatment of proliferative vitreoretinopathy : interrelationship with the coagulation cascade. In : Medical and surgical retina, advances, controversies, and management. Lewis H, Ryan SJ (eds.). 11830 Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc., 1993 L: 172.

Blumenkranz MS and Hartzel MK: The mechanism of action of drugs for the treatment of vitreoretinal scarring. In Ryan SJ, ed: Retina, 4th Edition, El-Servier Inc., USA, 2006, pp. 2241-2253.

Blumenkranz MS and Hartzel MK: The mechanism of action of drugs for the treatment of vitreoretinal scarring. In : Retina (second edition) (D-ROM edition). Ryan SJ, Glaser BM (eds). 11830 Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc., 1994; Chapter 142.

Blumenkranz MS, Hartzel MK and Iverson DA: An overview of potential application of heparin in vitreoretinal surgery (review). Retina 1992; 12 : 571-4.

Blumenkranz MS, Hernandez E, Ophir A and Norton EW: 5-fluorouracil : new application in complicated retinal detachment for an established antimetabolite. Ophthalmology 1984; 91 : 122 – 30.

Blumenkranz MS, Ophir A, Claflin A, et al.: Fluorouracil for the treatment of massive preretinal proliferation. Am J Ophthalmol 1982; 94: 458-467.

Bonnet M and Hajjar C: Clinical risk factors for proliferative vitreoretinopathy. In Stirpe M (Ed.): Advances in vitreoretinal surgery. Acta of the third international congress on vitreoretinal

surgery 1991, ophthalmic communications society Inc., New York 1992; pp. 229-236.

Bonnet M, Fleury J, Guenoun S, et al.: Cryopexy in primary rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy. Graefes Arch Clin Exp ophthalmol 1996; 234: 739-743.

Bonnet M: Clinical factors predisposing to massive proliferative vitreoretinopathy in rhegmatogenous retinal detachment. Ophthalmologica 1984; 188: 148-152.

Bonnet M: Macular changes and fluorescein angiographic changes after repair of proliferative vitreoretinopathy. Retina 1994; 14 : 404-10.

Bovey EH, DeAncos E and Gonvers M : Retinotomies of 180 degrees or more. Retina 1995; 15 : 394-8.

Brinton DA and Hilton GF: Pneumatic retinopexy and alternative retinal attachment techniques. In : Retina (Third edition). Ryan SJ (ed.). 11830 Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc., 2001: 2047 – 62.

Brown GC, Brown MM, Sharma S, Busbee B, and Landy J: A cost – utility analysis of intervention for severe proliferative vitreoretinopathy. Am J Ophthalmol 2002; 133 : 365 – 72.

Calabresi P and Parks RE: Chemotherapy of neoplastic diseases. In Googman AG, Oilman LS, Rail TW & Murad F (eds.): The pharmacological basis of therapeutics, McGraw-Hill Book Co, New York, 1985; pp 1248-1253.

Campochiaro PA and Glaser BM: Mechanisms involved in retinal pigment epithelial cell chemotaxis. Arch Ophthalmol 1986; 104: 277-280.

Campochiaro PA and Glaser BM: Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch Ophthalmol 1985; 103: 576-579.

Campochiaro PA, Bryan JA, Conway BP, et al.: Intravitreal chemotactic and mitogenic activity implications of blood retinal barrier breakdown. Arch Ophthalmol 1986; 104: 1685-1687.

Campochiaro PA, Hackett SF, and Conway BP: Retinoic acid promotes density-dependent growth arrest in human retinal pigment epithelial cells. Invest Ophthalmol Vis sci 1991; 32: 65-72.

Campochiaro PA, Jerdan JA, and Glaser BM: Serum contains chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol 1984; 102: 1830-1833.

Campochiaro PA, Sugg R, Grotendorst G and Hjelmeland LM: Retinal pigment epithelial cells produce PDGF-like proteins and secrete them into their media. Exp Eye Res 1989; 49: 217-227.

Campochiaro PA: Cell dedifferentiation in proliferative vitreoretinopathy. In Stirpe M (Ed.): Advances in vitreoretinal surgery. Acta of the third international congress on vitreoretinal surgery 1991, ophthalmic communications society Inc., New York 1992; pp. 229-236.

Campochiaro PA: The pathogenesis of proliferative vitreoretinopathy. In Ryan SJ (ed): Retina 2001 (3rd ed), Mosby Inc, pp. 2221-2227.

- Casaroli Marano RP and Vilaro S:** The role of fibronectin, laminin, vitronectin and their receptors on cellular adhesion in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1994; 35: 2791-2803.
- Cassidy L, Barry P, Shaw C, et al:** platelet derived growth factor and fibroblastic growth factor basic levels in patients with vitreoretinal disorders. Br J Ophthalmol 1998; 82: 181-185.
- Chandler DB, Hida T, Rozakis G, Forbes VS, and Machemer R:** The lack of an effect of intraocular steroids on irradiated fibroblast in experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1992; 230 : 188 – 92.
- Chapman C, Iverson D, Hartzer MK, Minelli E and Blumenkranz MS:** The effect of low molecular weight heparin on prliferative vitreoretinopathy induced in the rabbit eye. Invest Ophthalmol Vis Sci 1992; 33 (Suppl): 818.
- Charles S, Katz A and Wood B:** Proliferative vitreoretinopathy In: vitreous microsurgery, 3rd ed., Lippincott Williams & Wilkins, Philadelphia, 2002; pp. 136-152.
- Charteris DG, Ayelward W, Wong D, et al:** A randomized controlled trial of combined 5-Fluorouracil and low-molecular-weightheparin in management of established proliferative vitreoretinopathy. Ophthalmology 2004; 111:2240-2245.
- Charteris DG, Hiscott P, Grierson I and Lightman SL:** Proliferative vitreoretinopathy : lymphocytes in epiretinal membranes. Ophthalmology 1992; 99 : 1364 – 7.

- Charteris DG, Hiscott P, Robey HL, Gregor ZJ, Lightman SL and Grierson I:** Inflammatory cells in proliferative vitreoretinopathy subretinal membranes. *Ophthalmology* 1993;100 : 43 – 6.
- Charteris DG:** Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. *Br J Ophthalmol* 1995; 79: 953-960.
- Christmas NJ, Skolik DSA, Howard MA, Saito Y, Barnstable CJ and Liggett PE:** Treatment of retinal breaks with autologous serum in an experimental model. *Ophthalmology* 1995; 102 : 263 – 71.
- Clearly PE and Ryan SJ:** Methods of production and natural history of experimental posterior penetrating eye injury in the rhesus monkey. *Am J Ophthalmol* 1979; 88: 220-221.
- Coleman DJ, Lucas BC and Fleishmann JA:** A biological tissue adhesive for vitreoretinal surgery. *Retina* 1988; 8 :250 – 6.
- Conner TB, Roberts AB, Sporn MB, et al:** Correlation of fibrosis and transforming growth factor-B type 2 levels in the eye. *J Clin Invest* 1989; 83: 1661-1666.
- Cowley M, Conway B, Campochiaro P, et al:** Clinical risk factors for proliferative vitreoretinopathy. *Am J Ophthalmol* 1989; 107:1147- 1151.
- Dabour SA, Alkawas AA, Morshid MM, Elniel A and Hanifa HZ:** Triamcinolone – assisted pars plana vitrectomy in proliferative diabetic retinopathy and proliferative vitreoretinopathy. *Bull Ophthalmol Soc Egypt* 2004; 97 : 765 -9.

- Danis RP, Ciulla TA and Pratt LM:** Intravitreal triamcinolone acetonide in exudative age – related macular degeneration. *Retina* 2000; 20 : 244 – 50.
- Duquesene N, Bonnet M and Adeleine P.** Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?. *Graefes Arch Clin Exp Ophthalmology* 1996; 234: 677-82.
- Elnor SG, Elnor VM, Diaz-Rohena R, et al:** Anterior proliferative vitreoretinopathy: Clinicopathologic, light microscopic, and ultrastructural findings. *Ophthalmology* 1988; 95: 1349-1357.
- El-Toukhi EM and Adel SS:** Log-term use of silicone oil in certain cases of retinaldetachment. *Bull Ophthalmol Soc Egypt* 2001; 94 : 499 – 502.
- Esser P, Bresgen M, Weller M, Heimann K and Wiedemann P:** The significance of vitreonectin in proliferative diabetic retinopathy. *Graefes Arch Clin Exp Ophthalmol* 1994; 232: 477-481.
- Fathi A.** Adjuvant 5-fluorouracil and low molecular weight heparin during vitrectomy for cases of rhegmatogenous retinal detachment with ocular hypotony. *Bull Ophthalmol Soc Egypt* 2004; 97: 855-858.
- Fekrat S, de Juan E and Campochiaro PA:** The effect of oral 13-cis-retinoic acid on retinal detachment after surgical repair in eyes with proliferative vitreoretinopathy. *Ophthalmology* 1995; 102: 412-418.

- Ferrone BJ, McCuen BW II, DeJuan E and Machemer R:** The efficacy of silicone oil for complicated retinal detachment in the pediatric population. Arch Ophthalmol 1994; 112 : 773 -7.
- Fujii GY, DeJuan E and Humayun MS:** Initial experience using transconjunctival sutureless vitrectomy system for vitreoretinal surgery. Ophthalmology 2002; 109 : 1814 -20.
- Gabrielian K, Osusky R, Ryan SJ, et al:** The effect of transforming growth factor beta on interferon-gamma induced HL-DR expression in human RPE cells. Invest Ophthalmol Vis Sci 1993; 34 (suppl): 1019.
- Gad MA, El-Bendari AM and Zaky NS:** Triamcinolone – assisted pars plana vitrectomy in proliferative vitreoretinopathy. Bull Ophthalmol Soc Egypt 2004; 97 : 771 – 3.
- Gallemore RP, McCuen BW II:** Silicone oil in vitreoretinal surgery. In : Retina. Ryan SJ (ed.). 11830 Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc., 2001 : 2199.
- Gariano RK, Assil KK and Wiley CA:** Retina toxicity of the antimetabolite 5- fluorouridine 5 –monophosphate administration intravitreally using multivesicular liposomes. Retina 1994; 14 : 75 – 80.
- Girard P, Mimoun G, Karpouzas I and Montefiore G:** Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 1994; 14: 417-424.

- Glaser BM and Lemor M:** Pathobiology of proliferative vitreoretinopathy. In Ryan SJ (Ed.): Retina, 2nd Edition, Mosby-Year Book Inc., USA, 1994; pp. 2249-2264.
- Glaser BM, Cardin A and Biscoe B:** Proliferative vitreoretinopathy: the mechanism of development of vitreoretinal traction. Ophthalmology 1987; 94: 327 - 332.
- Glaser BM, Vidaurri-Leal J, Michels RG, et al:** Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology 1993; 100: 466-470.
- Glaser BM:** Surgery for proliferative vitreoretinopathy. In : Retina (Second edition) (CD-ROM edition). Ryan SJ, Glaser Bm (eds.). 11830 Westline Industrial Drive, St Louis, Missouri 63146. Mosby Inc., 1994; Chapter 141.
- Gonzalez-Avila G, Lozano D, Manjarrez ME, et al.:** Influence on collagen metabolism of vitreous from eyes with proliferative vitreoretinopathy. Ophthalmology 1995; 102: 1400-1405.
- Greenberg PB, Martidis A and Rogers AH:** Intravitreal triamcinolone acetonide for macular edema due to central retinal vein occlusion. Br J Ophthalmol 2002; 86 :247 -8.
- Grierson I, Heathcote L, Hiscott P, et al:** Hepatocyte growth factor/scatter factor in the eye. Prog Retin Eye Res 2000, 19: 779-802.
- Guerrin M, Moukadiri H, Chollet P, et al:** Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human

retinal pigment epithelial cells cultured in vitro. J Cell Physiol 1995; 64: 385-394.

Hagiwara T, Suzuki H, Kono I, et al: Regulation of fibronectin synthesis by Interleukin-6 in rat hepatocytes. Am J Pathol 1990; 133:39- 47.

Hartzer MK and Blumenkranz MS: Fluoropyrimidines in the treatment of proliferative vitreoretinopathy and glaucoma. In Tso and MOM, (ed.): Retinal diseases: biomedical foundations and clinical management, JB Lippincott Co, Philadelphia, 1988; pp. 347-361.

Harvey AK, Roberge F and Hjelmeland LM: Chemotaxis of rat retinal glia to growth factors found in repairing wounds. Invest Ophthalmol Vis Sci 1987; 28: 1092-1099.

Hinton DR, He S, Jin ML, Barron E and Ryan SJ: Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye 2002; 16 (4): 422-428.

Hiscott P, Sheridan C, Magee RM and Grierson I: Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog Retin Eye Res 1999; 18 : 167 – 90.

Hiscott P, Waller HA, Grierson I, Butler MG, Scott DL, Gregor Z and Morino I: Fibronectin synthesis in subretinal membranes of proliferative vitreoretinopathy. Br J Ophthalmol 1992; 76 : 486 – 90.

Hiscott PS, grierson I, Trombetta CJ, et al: Retinal and epiretinal glia- an immunohistochemical study. Br J Ophthalmol 1984; 68: 698-707.

Hui YN, Liang HC, Cai YS and Kirchhof B: Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol 1993; 231: 109 – 14.

Hutton WL, Azen SP and Blumenkranz MS for the Silicone Study Group: The effects of silicone oil removal. Silicone Study report 6. Arch Ophthalmol. 1994; 112 : 778 – 85.

Immonen I, Siren R, Liesto K, et al: Retinoids increase urokinase type plasminogen activator production by human retinal pigment epithelial cells in culture. Invest Ophthalmol Vis Sci 1993; 34: 2062-2067.

Inverson DA, Dailey WA, Hartzer MK, Chapman C and Blumenkranz MS: The effect of low molecular weight heparin on the mitogenicity of intraocular fluid from patients with proliferative retinopathies. Invest Ophthalmol Vis Sci 1991; 32 (suppl) : 879.

Iverson DA, Katsura H, Harzer MIC, et al: Inhibition of intraocular fibrin formation following infusion of low molecular weight heparin during vitrectomy. Invest Ophthalmol Vis Sci 1991b; 109: 405- 409.

Jaffe GJ, Ben-Nun J and Guo H: Flucinolone acetone sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 107 : 2024 – 33.

Jaffe GJ, Earnest K, Fulcher S, Lui Gm and Houston LL: Antitransferrin receptor immunotoxin inhibits proliferating human retinal pigment epithelial cells. Arch Ophthalmol 1990; 108: 1163-1168.

- Jaffe GJ, Harrison CE, Lui GM, et al:** Activin expression by cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1994; 35: 2924-2931.
- Jarus G, Blumenkranz MS, Hernandez E and Sossi N:** Clearance of intravitreal fluorouracil : normal and aphakic vitrectomized. Ophthalmology 1985; 92 : 91-6.
- Jerden A, Repose JS, Michel R, et al:** Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology 1989; 96: 801-810.
- Johnson NF and foulds WS:** Observations on the retinal pigment epithelium and retinal macrophages in experimental retinal detachment. Br J Ophthalmol 1977; 61: 564-572.
- Johnson RN and Blankenship G:** A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin. Ophthalmology 1988; 95 : 312 – 7.
- Jonas JB, Hyaler JK and Safker A :** Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131 : 468 – 71.
- Jonas JB, Kreissig I and Degenring R:** Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87 : 24 – 7.
- Jonas JB:** Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil. Br J Ophthalmol 2002 a; 86 : 1450 -1.

- Jonas JB:** Concentration of intravitreally injected triamcinolone acetonide in aqueous humour. *Br J Ophthalmol* 2002b; 86 : 1066.
- Kanaski J:** Clinical features of retinal detachment. In: *Clinical Ophthalmology – a systematic approach*, 4th ed., Butterworth Heimann (Elsevier Ltd), 2003, pp. 365-370.
- Kanaski J:** Clinical features of retinal detachment. In: *Clinical Ophthalmology – a systematic approach*, 6th ed., Butterworth Heimann (Elsevier Ltd), 2008, pp. 365-370.
- Kauffmann DJ, Meurs JC, Mertens DA, et al:** Cytokine in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci* 1994; 35: 900-906.
- Khattab AM:** Intraoperative visualization of the vitreous and the posterior hyaloids using triamcinolone acetonide in vitrectomy for proliferative vitreoretinopathy. *Bull Ophthalmol Soc Egypt* 2004; 97 : 733 – 7.
- Khaw PT and Migdal CS:** Current techniques in wound healing modulation in glaucoma surgery. *Current Opin Ophthalmol* 1996; 7 : 24 – 33.
- Khaw PT, Doyle JW and Sherwood MB:** Prolonged localized tissue effects from 5 – minute exposures to fluorouracil and mitomycinC. *Arch Ophthalmol* 1993; 111 : 263 -7.
- Khaw PT, Sherwood MB, MacKay SLD, Rossi MJ and Schultz G:** Five – minute treatment with fluorouracil, floxuridine, and mitiomycin have long term effects on human tenon's capsule fibroblasts. *arch Ophthalmol* 1992; 110 : 1150 – 4.

- Khawly JA, Saloupis P, Hatchell DL, and Machemer R:** Dauncorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1994; 229 : 464 -7.
- Kim IK and Arroyo JG:** Mechanisms in proliferative vitreoretinopathy. Ophthalmology clinics of North America 2002; 15 : number 1.
- Kivilcim M, Peyman GA and El-Dessouky ES:** Retinal toxicity of triamcinolone acetate in silicone – filled eyes. Ophthalmic Surg Lasers 2000; 20 : 474 – 8.
- Kon CH, Occleston NL, Ayelward GW and Khaw PT:** Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 1999; 40: 705-712.
- Kon CH, Occleston NL, Charteris D, et al:** A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1998; 39: 1524-1529.
- Kon CH, Occleston NL, Foss A, Sheridan C, Ayelward GW and Khaw PT:** Effects of single, short term exposures of human retinal pigment epithelial cells to thiotepa or 5 – fluorouracil : implications for treatment of proliferative vitreoretinopathy. Br J Ophthalmol 1998; 82 : 554 – 60.
- Kon CH, Occleston NL, Khaw PT and Ayelward GW:** Risk factors for proliferative vitreoretinopathy. Br J Ophthalmol 2000; 84: 506-511.
- Kosnosky W, Li TH and Palkins VA:** Interleukin -1- beta changes the expression of metalloproteinases in the vitreous humor and induces

membrane formation in eyes containing preexisting retinal holes.
Invest Ophthalmol Vis Sci 1994; 35 : 4260 – 7.

Laqua H and Machemer R: Clinical pathological correlation in massive preretinal proliferation. Am J Ophthalmol 1975; 80: 913.

Lean JS: Proliferative vitreoretinopathy. In Albert & Jakobiec (eds): principles and practice of ophthalmology, 2nd ed, Saunders WB comp., Philadelphia, 2000, pp 2392-2402.

Lean SJ : Proliferative vitreoretinopathy. In : Principles and practice of ophthalmology. Albert DM, Jakobie EA (eds.). Philadlephia : W.B. Saunders Company, A division of Harcourt Brace company, 1994 : 1110 – 21.

Lemor M, de Bustros S and Glaser BM: Low-dose colchicines inhibits astrocytes, fibroblast, and retinal pigment epithelial cell migration and proliferation, Arch Ophthalmol 1986; 104: 1223-1225.

Leschey KH, Hackett SF, Singer JH and Campochiaro PA: Growth factor responsiveness of human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1990; 31: 839-846.

Lewis H and Aaberg TM: Anterior proliferative vitreoretinopathy. Am J Ophthalmol 1988; 105:277-284.

Lewis H, Aaberg TM and Abrams GW: Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol 1991; 111 : 8.

Lewis H: Management of severe proliferative vitreoretinopathy. In Lewis H, Ryan SJ (eds): Medical and surgical retina, Mosby-Year Book, St. Louis, 1994, p 119.

Lewis JM, Abrams GW and Werner JC: Management of complicated retinal detachment. In : Ophthalmic Surgery : Principles and Techniques. Albert DM, Robinson NL (eds). USA : Blackwell Science Incorporated,1999 : 531 -64.

Limb GA, Earley O, Jones SE, LeRoy F, et al: Expression of mRNA coding for TNF alpha, IL-1 beta and IL-6 by cells infiltrating retinal membranes. Graefe Arch Clin Exp Ophthalmol 1994; 232: 646-651.

Limb GA, Little BC, Meager A, et al: Cytokines in proliferative vitreoretinopathy. Eye 1991; 5: 686-693.

Machemer R, Aaberg TM, Freeman HM, et al: An updated classification of retinal detachment with proliferative vitreoretinopathy, Am J Ophthalmol 1991; 112: 159- 165.

Machemer R: Proliferative vitreoretinopathy : a personal count of its pathogenesis and treatment. Invest Ophthalmol Vis sci 1988; 29 : 1771 – 83.

Macky TAA: Intravitreal mitomycin C-corticosteroids conjugate in inhibition of experimental proliferative vitreoretinopathy in an animal model. M.D. thesis in ophthalmology, Faculty of Medicine, Cairo University, Egypt, 2001.

Malbran E, Dodds RA, Hulsbus R, et al: Retinal break type and proliferative vitreoretinopathy in nontraumatic retinal detachment. Graefe Arch Clin Exp Ophthalmol 1990; 228: 423-425.

Martini B: Proliferative vitreoretinal disorders : experimental model in vivo and in vitro. Acta Ophthalmol 1992; 201 (Suppl): 1-63.

- Michaelson IC and Stein R:** A study in the prevention of retinal detachment. *Ann Ophthalmol* 1969; 1: 49.
- Michels R, Wilkinson C and Rice TA:** Retinal detachment. 11830 Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc., 1990: 680 – 705.
- Michels RG and Sjaarda RN:** Macular pucker. In : Retina (second edition) (CD-ROM edition). Ryan SJ, Glaser BM (eds.). 11830 Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc., 1994; Chapter 144.
- Mietz H and Heimann K:** Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal diseases. *Br J Ophthalmol* 1995; 79 : 874-7.
- Minihan M, Tanner V and Williamson TH:** Primary rhegmatogenous retinal detachment : 20 years of change. *Br J ophthalmol* 2001; 85 : 546 – 8.
- Morino I, Hiscott PS, Me Kechnie N, et al:** Variation in epiretinal membrane components with clinical duration of the proliferative tissue. *Br J Ophthalmol* 1990; 74: 393-399.
- Mruthyunjaya P and McCuen BW II:** Updated indications of silicone oil use in vitreoretinal surgery. *Highlights of Ophthalmology*; 2005; 33 : 9 – 13.
- Parel JM and Villain F:** Silicone oils physicochemical properties. In : Retina (Second edition) (CD – Rom edition). Ryan SJ, Glaser BM (eds.). 11830 Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc., 1994: Chapter 132

Pastor JC: Proliferative vitreoretinopathy : an overview. *Surv Ophthalmol* 1998; 43 : 3 -18.

Peczon BD, Wolfe JK, Gipson IK, et al: Characterization of membranes removed during open-sky vitrectomy. *Invest Ophthalmol Vis Sci* 1983; 24: 1382-1389.

Pieramici DJ, Caponi A and Aaberg TM: Surgical management of proliferative vitreoretinopathy. In : *Retina – vitreous – macula* (first edition). Guyer DR, Yanuzzi LA, Cahng S, Shields JA and Green WR(eds.). The Curits Center, Independence Square West, Philadelphia, Pennsylvania 19106 : W.B. Saunders Company, A division of Harcourt Health Science Company, 1999 : 1350 – 69.

Rachal WF and Burton TC: Changing concepts of failures after retinal detachment surgery. *Arch Ophthalmol* 1979; 97:180-183.

Radwan R, Hamdy AM, and El-Marakby M: Prophylactic treatment of retinal detachment following silicone oil removal. *Bull Ophthalmol Soc Egypt* 2001; 94 : 665 -7.

Regillo C, Chang TS, Johnson MW, Kaiser PK, Scott IU, Spaide R, and Griggs PB: Peripheral retinal abnormalities. In : *American academy of Ophthalmology, Basic and Clinical Science Course, Section 12, Retina and Vitreous*. Liesegang TJ, Skuta GL, and Cantor LB (eds). 655 Beach Street, Box 7424, San Francisco, CA 94120-7424 : American academy of Ophthalmology, 2004: 253 – 77.

Retina Society Terminology Committee: The classification of retinal detachment with PVR. *Ophthalmology* 1983; 90: 121-125.

- Reuter U, Champion C and Kain HL:** Transdifferentiation of human monocytes into fibroblast-like cells in vitro. *Ger J Ophthalmol* 1995; 4: 182-187.
- Robbins SG, Mixon RN, Wilson DJ, et al:** Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. *Invest Ophthalmol Vis Sci* 1994; 35: 3649-3663.
- Ross R, Raines EW and Bowen-Pope DF:** The biology of platelet derived growth factor. [Review]. *Cell* 1986; 46: 155-169.
- Ryan SJ:** The pathophysiology of PVR in its management. *Am J Ophthalmol* 1985; 100: 188-193.
- Ryan SJ:** Traction retinal detachment. XLIX Edward Jackson memorial lecture. *Am J Ophthalmol* 1993; 115 : 1-2.
- Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno T, Itaya K and Ishibshi T:** Triamcinolone – assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood – ocular barrier breakdown. *Graefes Arch Clin Exp Ophthalmol* 2002;240 : 423 -9.
- Schepens CL:** Proliferative Vitreoretinopathy (PVR). *Ophthalmology* 1987; 94: 201.
- Schepens CL:** Vitreous changes in rhegmatogenous retinal detachment. In Schepens CL, Hartnett ME and Hirose T (eds): *Schepens' retinal detachment and allied diseases*, Butterworth-Heinemann (Elsevier group), 2000, pp 153-179.

- Scott IU, Flynn HW and Azen SP:** Silicone oil in the repair of pediatric complex retinal detachments : prospective, observational, multicenter study. *Ophthalmology* 1999; 106 : 1399 – 407.
- Shoier A, Azab A and Rizk K:** Triamcinolone acetate – assisted pars plana vitrectomy. *Bull Ophthalmol Soc Egypt* 2004; 97 : 761 -4.
- Singh AK, Michels RG, Glaser BM:** Scleral indentation following cryotherapy and repeat cryotherapy enhance release of viable retinal pigment epithelial cells. *Retina* 1986; 6: 176- 178.
- Smith TR:** Pathological findings after retina surgery. In CL Schepens (ed): importance of the vitreous body in retina surgery with special emphasis on reoperations, C.V. Mosby Co., St Louis, 1960.
- Soliman MM and Ali KG:** Mitomycin –C in the management of proliferative vitreoretinopathy, randomized clinical study. *Bull Ophthalmol Soc Egypt* 2001; 94: 653 -8.
- Spee C, Hinton RT and Ryan SJ:** The potential of mitomycin C in the treatment of experimental proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci* 1996: 37 : 392 -8.
- Stefer U, Wiedemann P, Weber J and Heimann K :** functional results after vitrectomy with silicone oil injection. *Eur J Ophthalmol* 1991; 1 : 89 – 94.
- Stern WH, Lewis GP and Erickson PA:** Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. *Am J Ophthalmol* 1983; 96 : 33 – 42.

- Stilma JS, Koster R and Zivojnovic R:** Radical vitrectomy and silicone-oil injection in the treatment of proliferative vitreoretinopathy following retinal detachment. *Doc Ophthalmol* 1986; 64: 109-116.
- Takagi H, Tanihara H and Yoshimura N:** Gene expression of insulin-like growth factors and insulin-like growth factor binding proteins in cultured human retinal epithelial cells. *Invest Ophthalmol Vis Sci* 1993; 34(suppl): 1019.
- Tanihara H, Yoshida M, Masumoto M, et al:** Identification of transforming growth factor beta expressed in cultured retinal pigmentepithelial cells. *Invest Ophthalmol Vis Sci* 1993; 34: 413-419.
- Tano Y, Sugita G, Abrams G, et al:** Inhibition of intraocular proliferations with intravitreal corticosteroids. *Am J Ophthalmol* 1980; 89: 131-136.
- Thompson JT:** Complicated forms of retinal detachment: Proliferative vitreoretinopathy. In Ryan SJ (Ed.): *Retina*, 4th Edition, Mosby-Elsevier Inc., USA, 2006; pp. 2283-2309.
- Tseng W, Cortez RT, Ramirez G, et al:** Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. *Am J Ophthalmol* 2004; 137: 1105-1115.
- Van Bockxmeer FM, Martin CE, Thompson DE, et al:** Taxol for the treatment of proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci*, 1985; 26: 1140-1147.

- Van Ryn-McKenna J, Cai L and Ofosu FA:** Neutralization of enoxaparine – induced bleeding by protamine sulfate. *Thromb Homeos* 1990; 63 : 271 -4.
- Varga J, Rosenbloom J and Jimenez SA:** Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. *Biochem J* 1987; 247: 597-604.
- Verdoorn C, Renardel de Lavalette VWR, Delma-Weizhausz J, et al:** Cellular migration, proliferation and contraction: An in vitro approach to a clinical problem - Proliferative vitreoretinopathy. *Arch Ophthalmol* 1986; 104: 1216-1219.
- Verstraeten TC, Buzney SM, Macdonald SG and Neufeld AH:** Retinal pigment epithelium wound closure in vitro (pharmacologic inhibition). *Invest Ophthalmol Vis Sci* 1990; 31 : 481 – 8.
- Vidaurri-Leal J, Hohman R and Glaser BM:** Effect of vitreous on morphologic characteristics of retinal pigment epithelial cells: A new approach to the study of proliferative vitreoretinopathy. *Arch Ophthalmol* 1984; 102: 1220-1223.
- Vinores SA, Campochiaro PA and Conway B:** Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. *Invest Ophthalmol Vis Sci* (suppl)1993:983.
- Vinores SA, Henderer JD, Mahlow J et al:** Isoforms of platelet-derived growth factor and its receptors in epiretinal membranes: immunolocalization to retinal pigment epithelial cells. *Exp Eye Res* 1995;60: 607-619.

- Vinorez SA:** Ultrastructural and immunocytochemical changes in retinal pigment epithelium, retinal glia, and fibroblasts in vitreous culture. *Invest Ophthalmol Vis Sci* 1990; 31 : 2529 – 45.
- Walshe R, Esser P, Wiedemann P, et al:** Proliferative retinal diseases: myofibroblasts cause chronic vitreoretinal traction; *Br J Ophthalmol* 1992; 76: 550-552.
- Weller M, Wiedemann P and Heimann K:** PVR- is it anything more than wound healing at wrong place?. *Int Ophthalmol* 1990; 14 : 105-117.
- White HD, Gersh BJ and Opie LH:** Antithrombotic agents : platelet inhibitors, anticoagulants, and fibrinolytics. In : *Drugs for the heart* (fifth edition). Opie LH, Gersh BJ (eds.). The Curtis Center, Independence Square West, Philadelphia, Pennsylvania 19106: W.B. Saunders Company, A division of Harcourt health Science Company, 2001: 273 – 322.
- Wiedemann P, Leinung C, Hilgers RD and Heimann K:** Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. *Graefes Arch Clin Exp Ophthalmol* 1991; 229 : 150 – 5.
- Wiedemann P, Soregente N, Bekhor C, Paterson R, Tran T and Ryan SJ:** Daunomycin in the treatment of experimental proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci* 1985; 26 : 719 – 24.
- Williams GA and Aaberg TM:** Techniques of sclera buckling. In : *Retina* (third edition). Ryan SJ (ed.) 11830 Westline Industrial Drive, StLouis, Missouri 63146 : Mosby Inc., 2001: 2010 – 46.

- Wilson-Holt N, Khaw P, Savage F, et al:*** The chemoattractant activity of the vitreous to human scleral fibroblasts following retinal detachment and proliferative vitreoretinopathy. *Br J Ophthalmol* 1992; 76: 159-162.
- Yang CM and Cousins SW:*** Quantitative assessment of growth stimulating activity of the vitreous during PVR. *Invest Ophthalmol Vis Sci* 1992; 33: 2436-2442.
- Yang CS, Khawley JA, Hainsworth DP, et al:*** An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental PVR. *Arch Ophthalmol* 1998; 116: 69-77.
- Young S, Larkin and Branley M:*** Safety and efficacy of intravitreal triamcinolone acetonide for cystoid macular edema in uveitis. *Clin Exp Ophthalmol* 2001; 29 (Abstract): 206.
- Yu HG and Chung H:*** Antiproliferative effect of mitomycin C on experimental proliferative vitreoretinopathy in rabbits. *Korean J Ophthalmol* 1997; 11: 98-105.